Learning Deep Architectures for Interaction Prediction in
  Structure-based Virtual Screening by Gonczarek, Adam et al.
Learning Deep Architectures for Interaction
Prediction in Structure-based Virtual Screening
Adam Gonczarek, Jakub M. Tomczak, Szymon Zare˛ba, Joanna Kaczmar
Wrocław University of Science and Technology
adam.gonczarek@pwr.edu.pl
Piotr Da˛browski, Michał J. Walczak
Indata SA
Abstract
We introduce a deep learning architecture for structure-based virtual screening
that generates fixed-sized fingerprints of proteins and small molecules by applying
learnable atom convolution and softmax operations to each compound separately.
These fingerprints are further transformed non-linearly, their inner-product is
calculated and used to predict the binding potential. Moreover, we show that
widely used benchmark datasets may be insufficient for testing structure-based
virtual screening methods that utilize machine learning. Therefore, we introduce
a new benchmark dataset, which we constructed based on DUD-E and PDBBind
databases.
1 Introduction
Virtual screening is one of the leading methods in computational drug discovery, which aims at
identification of novel small molecules that are capable of binding a drug target, usually a protein.
In short, there are two main approaches of virtual screening, ligand-based and structure-based.
Ligand-based virtual screening relies on empirically established data, which provide information on
active (binding compounds later called ligands) and inactive (not binding) molecules. This approach
exploits chemical and spatial similarity among binders to identify new ligands of proteins. The
second approach, structure-based virtual screening, requires structural information of a protein to
dock a ligand candidate in the binding pockets of a target. Here, a large number of small molecules
is screened against a structure of a target protein. Then, binding capacity between protein and
compounds is assessed using scoring functions, and finally compounds are triaged according to their
binding potential.
The main hurdles affecting virtual screening is complexity of chemical space comprising up to 1060
theoretical [1] and 107 of commercially available compounds [4]1, as well as high false positive rate
of identified ligands and a lack of exhaustive training datasets.
Although the above mentioned hindrances are tackled by various approaches, e.g. Smina [5], with
different success rate, it is the advent of deep learning that promises superior performance in
high-throughput virtual screening [13]. Deep learning has already been successfully employed in
ligand-based virtual screening [2, 7, 10] but only recently the very first attempts to the structure-based
methods have emerged [9, 14].
1http://zinc15.docking.org/
Workshop on Machine Learning in Computational Biology. 30th Conference on Neural Information Processing
Systems (NIPS 2016), Barcelona, Spain.
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In this study, we propose a new deep architecture for predicting binding capacity of a protein-
molecule pair. In addition, we demonstrate the disadvantages of common benchmark datasets, which
are used for training and testing screening methods. To fill this gap, we propose a new benchmark
dataset that is more suitable for structure-based virtual screening.
2 Methodology
Model Our aim is to predict binding potential y ∈ {0, 1} for given pair of a small molecule l and
a target (represented by a pocket in protein structure to which a ligand may bind) p. We face three
major problems in the stated task: (i) both target and small compound vary in size, (ii) each of them
is represented by a list of atoms and therefore a method must be invariant to any permutation of the
list, (iii) these are 3D structures, thus a method must be invariant to translations and rotations. To
cope with these issues we propose to process the protein and the small molecule separately to obtain
two fixed-size descriptions (fingerprints) that can be further transformed non-linearly e.g. by neural
nets, and finally used for binding prediction. This approach aims at processing the protein-compound
pair separately and then learning a relation of the interaction. A pipeline of the proposed method is
presented in Figure 1(a).
Figure 1: (a) Schema of the proposed approach. Letters A and P denote lists of atoms and connections,
respectively. (b) Details about the neural fingerprint.
The crucial part of the proposed approach is a fingerprint, i.e., a description of a fixed size. One of
the widely used fingerprints for virtual screening is Extended Connectivity Fingerprint (ECFP) [11].
ECFP is an automatic manner of determining fingerprints by consecutively applying a hash function
on atom and its neighborhood followed by a indexing operation. The hash function allows to combine
information about each atom and its neighboring substructures while the indexing operation is used
to combine all the nodes’ features into a single fingerprint of the whole compound. However, due to
pre-determined form of hashing and indexing, ECFP is sensitive to small perturbations in molecule
structure, and therefore the features obtained by this method are not very robust.
Very recently, the drawbacks of ECFP were alleviated by application of learnable operations sim-
ilar to operations in convolutional neural nets [2]. Here the hashing is replaced with an adaptive
convolutional-like operation and the indexing with a softmax operation. This could be formalized as
follows. Let us denote an mth atom in a compound described by F features by am. Then hashing
could be described in the following fashion:
am := σ
(
Wam +
Im∑
i=1
HImai + b
)
, (1)
where ai is ith neighboring atom, Im is the number of possible neighbors for the mth atom2,
W ∈ RR×F is a matrix of weights3, H1, . . . ,H5 ∈ RR×F are matrices of weights for neighbors,
b ∈ RR is a bias vector, and σ(·) is an element-wise non-linear function, e.g., the sigmoid function
or ReLU. We refer to this operation as atom convolution and it can be repeated K times which
constitutes K layers, and each layer consists of own weights to learn (see Fig. 1(b)).
2Due to the physical properties of compounds there can be only up to 5 neighbors, so Im ∈ {1, 2, . . . , 5}.
3Notice that R is the number of new features and this could differ from F .
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The indexing operation is then replaced with a softmax operation that consecutively applies the
softmax function to each atom in the compound to yield the final neural fingerprint n:
n =
∑
m
sofmax(Vam + c) (2)
where V ∈ RS×R is a weight matrix, c ∈ RS is a bias vector and S is the size of the fingerprint.
Next, after obtaining the neural fingerprint for small compound (nl) and protein (np), we apply
a neural network (MLP) to obtain new representations: w = MLPl(nl) and v = MLPp(np).
Eventually, we calculate the bioactivity by transforming the inner product of w and v using the
sigmoid function sigm(·):
y(l, p) = sigm(w>v). (3)
Training Standard learning of neural networks utilizes the cross-entropy (CE) loss function. Typi-
cally databases contain only active ligand-protein pairs. Hence, we propose to add an additional term
to the CE loss in order to avoid overfitting to the positive class:
L(θ) = 1
N
N∑
n=1
log y(ln, pn) + El,p∼P (l,p)[log(1− y(l, p))]. (4)
Despite the fact that the expected value can be approximated using Monte Carlo methods, this
formulation causes a problem since finding the joint probability of the small molecule-protein pair is
a very complex task. We overcome this issue with the assumption that taking a random pair from the
dataset would result in a negative (not binding) example. Obviously, such an approach introduces a
bias, however, a chance of producing wrong label is negligible. The proposed loss function in (4) is
closely related to the Noise Contrastive Estimation [3].
3 Results
The efficacy of machine learning methods for virtual screening are typically evaluated with one of
the renowned benchmarks, e.g., DUD-E [8]. Generally, the evaluation dataset is divided into training
and testing sets that contain different targets (together with their actives and decoys). Interestingly,
it turns out that this testing protocol might be strongly biased due to similarity of artificial decoys
for different targets. We addressed this problem with a newly developed benchmark based on two
separate datasets.
Table 1: Results on DUD-E benchmark (70%
of data for training and 30% of data for test-
ing) and on DUD benchmark (leave-one-out cross-
validation).
Dataset Method Mean AUC
DUD-E Smina 0.700
AtomNet [14] 0.855
cmpds ECFP + LR 0.904
DUD DeepVS [9] 0.800
DUD-E experiment We used DUD-E4 bench-
mark, consisting of 102 proteins (targets),
22, 886 active compounds (ligands or binders)
and over 1M decoys (non-binders). We ran-
domly divided targets into training (72) and test-
ing (30) parts, which is similarly to [14]. We ap-
plied the ECFP fingerprint with the size of 4096
to small compounds (cmpds) only and trained
logistic regression (LR) to discriminate between
actives and decoys. Notice that no information
about targets was used. The method achieved
0.904 mean AUC, evaluated on the targets in the
test set, and to the best of our knowledge it has outperformed other state-of-the-art methods for
structure-based virtual screening trained in the similar manner (see Table 1). Thus, this suggests that
datasets with many artificially generated decoys (like DUD-E) are prone to bias due to similarity of
majority of the inactive compounds for one target to inactive compounds for other targets. Further,
application of basic learning methods to small compounds only results in improved performance.
Consequently, it is uncertain whether a method evaluated on this testing scheme learns the relationship
between compounds and targets, or learns the discrimination between active and inactive molecules,
where additional information about targets only contributes to noise.
4http://dude.docking.org/
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PDBBind + DUD-E Next, we employed PDBBind [6] for training and DUD-E for testing. The
original PDBBind database contains 3D structures of about 10k complexes, i.e., structures of ligands
docked in binding pockets of proteins. We have removed all the complexes containing targets from
DUD-E, obtaining 8822 complexes for training. Notice that this dataset contains no artificially
generated decoys, negative examples are generated by sampling random target-compounds pairs
from the dataset (see Eq. 4). For testing we used 88 DUD-E targets represented by a binding pocket
extracted from the original PDBBind. For each target we have randomly sampled 1000 compounds
(actives and decoys) from DUD-E, resulting in 88, 000 testing examples. We tested two different
models based on the pipeline presented in Fig. 1(a). In the first model, standard ECFP fingerprints
were applied both to small compounds and pockets. In the second one we adopted learnable neural
fingerprints. We compared our approach to two widely used methods, i.e., AutoDock Vina [12] and
Smina [5]. The results are presented in Table 2. First, we see the importance of applying learnable
fingerprint, since ECFP performed worse than the reference methods. Second, we observe that the
neural fingerprint-based approach outperformed both reference methods, achieving better mean AUC,
and reaching more targets that exceeded high AUC thresholds.
Table 2: Results obtained on the proposed benchmark. The presented approach with ECFP is denoted
by Ours(ECFP) and the one with neural fingerprint by Ours(NF). AUC ≥ α denotes on how many
targets (out of 88) a method performs better than α.
Method Total AUC Mean AUC (± std.) AUC ≥ 0.7 AUC ≥ 0.8 AUC ≥ 0.9
AutoDock Vina 0.644 0.691± 0.147 47 21 4
Smina 0.653 0.704± 0.138 54 23 4
Ours(ECFP) 0.600 0.551± 0.166 21 2 0
Ours(NF) 0.714 0.705 ± 0.168 47 29 11
4 Conclusions
This study results in two contributions in the field of computational drug discovery. First, we propose
a new benchmark dataset built on top of the two established datasets, PDBBind and DUD-E. This
benchmark provides suitable information for the development of structure-based virtual screening
methods. At the same time, we demonstrate that currently available benchmarks represent mediocre
training and testing sets due to insufficient coverage of chemical complexity. Second, we propose
a novel deep learning-based approach able to identify ligands of target protein. The performed
experiments showed that our approach outperforms two widely used methods, AutoDock Vina and
Smina. Here developed method reaches AUC of 0.9 or greater for the 11 targets, while the reference
methods exceed AUC of 0.9 for the 4 targets. We anticipate further evolution of the proposed
approach by applying more sophisticated deep learning techniques, e.g. by developing more accurate
learnable fingerprints.
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